IL13R alpha 2 CAR-T is under clinical development by TCR Cure Biopharma Technology and currently in Phase I for Glioma.
Nvidia’s biotech moment; Regeneron launches venture arm; New GLP-1 player enters; Sanofi rejigs cancer pact, vaccine ops; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit